Table 1 Baseline characteristics of TyG quartile-based grouping
TyG quartile | Overall | Q1 | Q2 | Q3 | Q4 | p-value |
|---|---|---|---|---|---|---|
N | 1,965 | 491 | 491 | 491 | 492 | |
Admission age (years, IQR) | 71.97 (60.55–82.76) | 76.75 (63.85–86.55) | 75.45 (63.11–84.06) | 71.78 (60.01–82.23) | 67.07 (56.45–76.87) | < 0.001 |
Weight (Kg, IQR) | 77.00 (64.00–91.00) | 71.80 (61.10–82.40) | 75.30 (63.00–89.80) | 78.50 (65.60–94.10) | 83.00 (68.40–99.50) | < 0.001 |
INR (IQR) | 1.10 (1.00–1.20) | 1.10 (1.00–1.20) | 1.10 (1.00–1.20) | 1.10 (1.00–1.20) | 1.10 (1.00–1.20) | 0.363 |
PT (Second, IQR) | 12.20 (11.30–13.70) | 12.30 (11.40–13.70) | 12.20 (11.35–13.95) | 12.10 (11.30–13.50) | 12.20 (11.30–13.80) | 0.579 |
PTT (Second, IQR) | 28.00 (25.50–31.50) | 28.50 (25.80–31.70) | 28.00 (25.55–31.80) | 27.60 (25.50–31.00) | 27.70 (24.90–31.40) | 0.045 |
WBC (K/ul, IQR) | 9.60 (7.50–12.70) | 8.60 (6.70–10.60) | 9.50 (7.40–12.30) | 10.20 (8.25–13.30) | 10.90 (8.20–14.70) | < 0.001 |
Glucose (mg/dL, IQR) | 123.00 (103.00–157.00) | 102.00 (91.00–119.50) | 116.00 (101.50–137.00) | 131.00 (111.00–159.00) | 170.00 (133.00–235.25) | < 0.001 |
Chloride (mg/dL, IQR) | 103.00 (100.00–106.00) | 104.00 (101.00–107.00) | 104.00 (101.00–106.00) | 103.00 (100.00–106.00) | 102.00 (99.00–105.00) | < 0.001 |
Triglycerides (mg/dL, IQR) | 104.00 (76.00–147.00) | 66.00 (55.00–77.50) | 93.00 (79.00–109.00) | 122.00 (101.00–148.00) | 186.50 (144.00–258.25) | < 0.001 |
TyG (IQR) | 8.80 (8.40–9.24) | 8.16 (8.00–8.30) | 8.60 (8.52–8.70) | 9.00 (8.89–9.11) | 9.63 (9.40–10.02) | < 0.001 |
RBC (m/ul, IQR) | 4.26 (3.80–4.70) | 4.17 (3.77–4.56) | 4.26 (3.75–4.66) | 4.33 (3.85–4.75) | 4.34 (3.79–4.78) | < 0.001 |
Platelet (K/uL, IQR) | 217.00 (171.00–271.00) | 210.00 (161.50–259.00) | 214.00 (177.00–269.00) | 218.00 (174.50–271.50) | 222.00 (173.75–286.00) | 0.026 |
Heart rate (beats/min, IQR) | 80.00 (69.00–92.00) | 78.00 (67.00–89.00) | 80.00 (70.00–92.00) | 79.00 (69.00–91.00) | 84.00 (72.00–96.00) | < 0.001 |
Respiratory rate (bpm, IQR) | 18.00 (15.00–22.00) | 18.00 (15.00–21.00) | 18.00 (15.00–21.00) | 18.00 (16.00–22.00) | 19.00 (16.00–22.00) | 0.009 |
SBP (mmHg, IQR) | 141.00 (125.00–157.00) | 140.00 (125.00–156.00) | 142.00 (126.50–156.00) | 142.00 (127.00–158.00) | 142.00 (124.00–157.00) | 0.558 |
DBP (mmHg, IQR) | 77.00 (66.00–89.00) | 77.00 (66.00–87.00) | 77.00 (67.00– 88.00) | 76.00 (66.00–89.00) | 77.50 (66.75–91.00) | 0.645 |
SOFA (Score, IQR) | 3.00 (2.00–5.00) | 3.00 (2.00–4.00) | 3.00 (2.00–5.00) | 3.00 (2.00–5.00) | 4.00 (2.00–6.00) | < 0.001 |
Sex (n,%) | 0.429 | |||||
Male | 986 (50.18%) | 260 (52.95%) | 241 (49.08%) | 249 (50.71%) | 236 (47.97%) | |
Female | 979 (49.82%) | 231 (47.05%) | 250 (50.92%) | 242 (49.29%) | 256 (52.03%) | |
Ethnicity (n,%) | 0.155 | |||||
Black | 1208 (61.48%) | 313 (63.75%) | 311 (63.34%) | 289 (58.86%) | 295 (59.96%) | |
White | 184 (9.36%) | 53 (10.79%) | 44 (8.96%) | 39 (7.94%) | 48 (9.76%) | |
Others | 573 (29.16%) | 125 (25.46%) | 136 (27.70%) | 163 (33.20%) | 149 (30.28%) | |
Myocardial infarction (n,%) | 0.028 | |||||
No | 1704 (86.72%) | 443 (90.22%) | 429 (87.37%) | 415 (84.52%) | 417 (84.76%) | |
Yes | 261 (13.28%) | 48 (9.78%) | 62 (12.63%) | 76 (15.48%) | 75 (15.24%) | |
Congestive heart failure (n,%) | 0.281 | |||||
No | 1578 (80.31%) | 399 (81.26%) | 395 (80.45%) | 403 (82.08%) | 381 (77.44%) | |
Yes | 387 (19.69%) | 92 (18.74%) | 96 (19.55%) | 88 (17.92%) | 111 (22.56%) | |
Peripheral vascular disease (n,%) | 0.783 | |||||
No | 1779 (90.53%) | 443 (90.22%) | 440 (89.61%) | 449 (91.45%) | 447 (90.85%) | |
Yes | 186 (9.47%) | 48 (9.78%) | 51 (10.39%) | 42 (8.55%) | 45 (9.15%) | |
Dementia (n,%) | 0.015 | |||||
No | 1837 (93.49%) | 446 (90.84%) | 457 (93.08%) | 463 (94.30%) | 471 (95.73%) | |
Yes | 128 (6.51%) | 45 (9.16%) | 34 (6.92%) | 28 (5.70%) | 21 (4.27%) | |
Paraplegia (n,%) | 0.204 | |||||
No | 916 (46.62%) | 224 (45.62%) | 214 (43.58%) | 231 (47.05%) | 247 (50.20%) | |
Yes | 1049 (53.38%) | 267 (54.38%) | 277 (56.42%) | 260 (52.95%) | 245 (49.80%) | |
Renal disease (n,%) | 0.003 | |||||
No | 1673 (85.14%) | 437 (89.00%) | 421 (85.74%) | 418 (85.13%) | 397 (80.69%) | |
Yes | 292 (14.86%) | 54 (11.00%) | 70 (14.26%) | 73 (14.87%) | 95 (19.31%) | |
Atrial fibrillation (n,%) | < 0.001 | |||||
No | 1255 (63.87%) | 296 (60.29%) | 283 (57.64%) | 326 (66.40%) | 350 (71.14%) | |
Yes | 710 (36.13%) | 195 (39.71%) | 208 (42.36%) | 165 (33.60%) | 142 (28.86%) | |
Diabetes (n,%) | < 0.001 | |||||
No | 1371 (69.77%) | 439 (89.41%) | 396 (80.65%) | 326 (66.40%) | 210 (42.68%) | |
Yes | 594 (30.23%) | 52 (10.59%) | 95 (19.35%) | 165 (33.60%) | 282 (57.32%) | |
Antihyperglycemic (n,%) | 0.003 | |||||
No | 1950 (99.24%) | 486 (98.98%) | 490 (99.80%) | 491 (100.00%) | 483 (98.17%) | |
Yes | 15 (0.76%) | 5 (1.02%) | 1 (0.20%) | 0 (0.00%) | 9 (1.83%) | |
Antihyperlipidemic (n,%) | 0.900 | |||||
No | 1197 (60.92%) | 302 (61.51%) | 303 (61.71%) | 299 (60.90%) | 293 (59.55%) | |
Yes | 768 (39.08%) | 189 (38.49%) | 188 (38.29%) | 192 (39.10%) | 199 (40.45%) |